O

Omeros Corp
D

OMER

3.15000
USD
-0.06
(-1.87%)
مغلق
حجم التداول
26,687
الربح لكل سهم
-2
العائد الربحي
-
P/E
-1
حجم السوق
184,566,416
أصول ذات صلة
A
ARWR
-0.250
(-1.62%)
15.140 USD
F
FATE
-0.02000
(-1.68%)
1.17000 USD
M
MDGL
-5.51
(-2.02%)
267.27 USD
M
MRSN
-0.02890
(-7.57%)
0.35270 USD
M
MRUS
13.405
(32.12%)
55.140 USD
S
SRPT
-0.900
(-2.32%)
37.900 USD
المزيد
الأخبار المقالات

العنوان: Omeros Corp

القطاع: Healthcare
الصناعة: Biotechnology
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.